Fulltext

Hematopoetic stem cell transplantation for solid tumors in Europe

Gratwohl, A. ; Baldomero, H. ; Demirer, T. ; Rosti, G. ; Dini, G. ; Ladenstein, R. ; Urbano-Ispizua, A.

In: Annals of Oncology, 2004, vol. 15, no. 4, p. 653-660

Add to personal list
    Title
    • Hematopoetic stem cell transplantation for solid tumors in Europe
    Author
    • Gratwohl, A.. Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, Switzerland
    • Baldomero, H.. Division of Hematology, Department of Internal Medicine, Kantonsspital Basel, Switzerland
    • Demirer, T.. EBMT Office, Ankara University Medical School, Ibn-i Sina Hospital, Sihhiye, Ankara, Turkey
    • Rosti, G.. Oncology-Hematology Department, Ospedale Civile, Ravenna
    • Dini, G.. Department of Pediatric Hematology & Oncology, Institute G. Gaslini, Genova, Italy
    • Ladenstein, R.. BMT Unit, St Anna Kinderspital, Vienna, Austria
    • Urbano-Ispizua, A.. EBMT Secretariat, Hospital Clinic, Barcelona, Spain
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Annals of Oncology, 2004, vol. 15, no. 4, p. 653-660. Oxford University Press
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:302838
    Summary
    Background: Hematopoetic stem cell transplants (HSCT) are discussed as treatment options for patients with solid tumors. Transplant numbers have changed substantially over the last decade, few controlled studies are available and different opinions prevail. Objective information on current practice is needed. Patients and methods: Data from 27 902 HSCT for solid tumors (2% allogeneic, 98% autologous), collected by the European Group for Blood and Marrow Transplantation (EBMT) activity survey from 1991 to 2002 were used to assess trends, transplant rates and coefficient of variation of transplant rates in Europe. Results: Transplant numbers increased from 536 in 1991 to 4154 in 1997 and decreased to 1913 in 2002. Indications were neuroblastoma (2504 HSCT; 9%), glioma (662 HSCT; 2%), soft tissue sarcoma (1253 HSCT; 4%), germ cell cancer (3291 HSCT; 12%), breast cancer (13 524 HSCT; 48%), Ewing's sarcoma (1896 HSCT; 7%), lung cancer (387 HSCT; 1%), ovarian cancer (845 HSCT; 3%) and other solid tumors (3540 HSCT; 14%). Allogeneic cells were used in <20 cases up to 1997; since then allogeneic HSCT increased to 159 in 2002, mainly for renal cell carcinoma. Low coefficients of variation in transplant rates (<60%) are observed for Ewing's sarcoma (<56.5%), suggesting consensus for this indication. Conclusions: These data give an overview on current practice of HSCT for solid tumors in Europe. They provide objective information for health-care providers and patient counselling